Sensile Medical Enters into an Agreement with scPharmaceuticals
News May 01, 2013
Sensile Medical AG has entered into a strategic partnership and supply agreement with scPharmaceuticals LLC to develop and manufacture an automated patch pump that delivers furosemide subcutaneously.
Furosemide is a diuretic that forms the cornerstone of heart failure therapy and is currently used in tablet form or in solution for intravenous administration. scPharmaceuticals has developed a proprietary subcutaneous formulation of furosemide and will use Sensile Medical’s patented SenseCore technology platform to deliver the drug in a patient-friendly and automated way. scPharmaceuticals will start its late-stage clinical development phase in the near future and expects to submit the New Drug Application for the furosemide drug device combination not later than Q1 of 2015.
“We are very pleased to enter this collaboration with scPharmaceuticals” said Derek Brandt, CEO of Sensile Medical. “We believe that our micro pump technology has the potential to address some important therapeutic and economic challenges that the medical community is facing today. “
“The Affordable Care Act has created an urgent need for novel therapies that offer benefits comparable to those achieved by intravenously administered drugs in the hospital, but which can be administered anytime anywhere by the patient”, said Pieter Muntendam, MD, President and CEO of scPharmaceuticals, “The SenseCore Micro-Pump technology stands out because of its precision and the unique and cost-effective two component design.”
Under the terms of the agreement, Sensile Medical will design, develop, and manufacture patch pumps for scPharmaceuticals’ proprietary subcutaneous formulation of furosemide. Furthermore, it establishes a strategic partnership between Sensile Medical and scPharmaceuticals to work together to develop further medications utilizing Sensile’s technology platform. Terms of the agreement were not disclosed.
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018